Kura Oncology (NASDAQ:KURA) Stock Price Down 2.3%

Kura Oncology, Inc. (NASDAQ:KURA)’s share price dropped 2.3% on Tuesday . The stock traded as low as $20.33 and last traded at $20.39. Approximately 12,316 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 952,298 shares. The stock had previously closed at $20.87.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, Stifel Nicolaus cut their target price on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.60.

Kura Oncology Stock Performance

The business’s fifty day moving average is $20.31 and its two-hundred day moving average is $20.64. The stock has a market capitalization of $1.58 billion, a PE ratio of -9.40 and a beta of 0.84. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of Kura Oncology during the 1st quarter valued at approximately $110,000. Saxon Interests Inc. bought a new position in Kura Oncology during the first quarter valued at $201,000. Quarry LP purchased a new stake in shares of Kura Oncology in the second quarter valued at $196,000. Entropy Technologies LP bought a new stake in shares of Kura Oncology in the 1st quarter worth about $218,000. Finally, Cape Investment Advisory Inc. purchased a new position in shares of Kura Oncology during the 4th quarter worth about $176,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.